Goetz MP et al. -Abemaciclib is effective in women with HR–positive, HER2–negative advanced breast cancer previously treated with endocrine therapy.Abemaciclib in combination with a non-steroidal aromatase inhibitor was shown to significantly improve PFS and ORR in such women.